| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Nuclear Medicine, Department of Radiology
Division of Pulmonary and Critical Care, Department of Medicine
Division of Thoracic Surgery, Department of Surgery
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Correspondence: For correspondence or reprints contact: Abass Alavi, MD, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA, 19104.
ABSTRACT
Despite several attempts at treating malignant pleural mesothelioma with various modalities, mortality remains high, with median survival between 12 and 18 mo. This disease may have a highly variable clinical course, with occasional long-term survivors. The purpose of this study was to assess whether tumor metabolic activity, as assessed by fluorodeoxyglucose (FDG) PET imaging, correlates inversely with survival. Methods: Twenty-eight patients with suspected mesothelioma underwent FDG PET scanning between September 1995 and May 1997. A diagnosis of mesothelioma was confirmed in 22. Fully corrected scans with attenuation correction of the entire chest were available in 17 patients with sufficient follow-up for survival analysis. Standardized uptake values (SUVs) were determined from the most active tumor site in each patient. Results: Seven patients died during follow-up, at a median period of 5.3 mo after FDG PET scanning. Follow-up information was available on the remaining 10 patients for a median period of 15.6 mo after the PET study. The mean SUV of the deceased patients was 6.6 ± 2.9, compared with 3.2 ± 1.6 among the combined survivors. The deceased patients had tumor SUVs that were highly correlated with duration of survival after the PET study (r = 0.87, P < 0.05). The cumulative survival estimate by the Kaplan-Meier product limit method was 0.17 at 12 mo for the patients with tumor SUVs greater than the median value and 0.86 for those with lower SUVs. The survival distribution of the high SUV group showed significantly shorter survivals compared with the low SUV group (P < 0.01) Conclusion: Patients with highly active mesotheliomas on FDG PET imaging have a poor prognosis. High FDG uptake in these tumors indicate shorter patient survival.
Key Words: fluorodeoxyglucose • PET • mesothelioma • survival
This article has been cited by other articles:
|
|
 |
|
  R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Barreiro and P. J. Katzman Malignant Mesothelioma: A Case Presentation and Review J Am Osteopath Assoc, December 1, 2006; 106(12): 699 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Flores, T. Akhurst, M. Gonen, M. Zakowski, J. Dycoco, S. M. Larson, and V. W. Rusch Positron emission tomography predicts survival in malignant pleural mesothelioma J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 763 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 920 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Sterman, A. Recio, A. Vachani, J. Sun, L. Cheung, P. DeLong, K. M. Amin, L. A. Litzky, J. M. Wilson, L. R. Kaiser, et al. Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy Clin. Cancer Res., October 15, 2005; 11(20): 7444 - 7453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Melloni, J. Monteil, F. Vincent, F. Bertin, S. Gaillard, T. Ducloux, S. Verbeke, A. Maubon, J-C. Vandroux, and F. Bonnaud Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases Eur. Respir. J., November 1, 2004; 24(5): 814 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Larson Positron Emission Tomography-Based Molecular Imaging in Human Cancer: Exploring the Link between Hypoxia and Accelerated Glucose Metabolism Clin. Cancer Res., April 1, 2004; 10(7): 2203 - 2204. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. J. Wang, G. P. Reddy, M. B. Gotway, C. B. Higgins, D. M. Jablons, M. Ramaswamy, R. A. Hawkins, and W. R. Webb Malignant Pleural Mesothelioma: Evaluation with CT, MR Imaging, and PET RadioGraphics, January 1, 2004; 24(1): 105 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Stewart, D. Waller, J. Edwards, K. Jeyapalan, and J. Entwisle Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma? Eur. J. Cardiothorac. Surg., December 1, 2003; 24(6): 1019 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V H Gerbaudo, S Britz-Cunningham, D J Sugarbaker, and S T Treves Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma Thorax, December 1, 2003; 58(12): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, K. Matzie, J. Friedberg, J. C. Kucharczuk, L. A. Litzky, S. W. Johnson, L. R. Kaiser, et al. Gene Expression Profiling of Malignant Mesothelioma Clin. Cancer Res., August 1, 2003; 9(8): 3080 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H. Gerbaudo, D. J. Sugarbaker, S. Britz-Cunningham, M. F. Di Carli, C. Mauceri, and S. T. Treves Assessment of Malignant Pleural Mesothelioma with 18F-FDG Dual-Head Gamma-Camera Coincidence Imaging: Comparison with Histopathology J. Nucl. Med., September 1, 2002; 43(9): 1144 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franzius, S. Bielack, S. Flege, J. Sciuk, H. Jurgens, and O. Schober Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma J. Nucl. Med., August 1, 2002; 43(8): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, J. M. Aronchick, and A. Alavi Accuracy of F-18 Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Malignancy in Patients Presenting With New Lung Abnormalities : A Retrospective Review Chest, December 1, 2001; 120(6): 1791 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schouwink, E. T. Rutgers, J. van der Sijp, H. Oppelaar, N. van Zandwijk, R. van Veen, S. Burgers, F. A. Stewart, F. Zoetmulder, and P. Baas Intraoperative Photodynamic Therapy After Pleuropneumonectomy in Patients With Malignant Pleural Mesothelioma : Dose Finding and Toxicity Results Chest, October 1, 2001; 120(4): 1167 - 1174. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
